
Index

Abortion – see also Prenatal testing

- Australian Capital Territory
 - criminalisation to medicalisation, 853-854
- medical – *see* **Medical abortion**
- New South Wales, 850-863
 - overview, 851-853
 - recognition of reproductive rights, 854-862
 - access to mifepristone, 862
 - adequate provision of facilities statewide, 861-862
 - decriminalising without medicalising, 855-858
 - legislated exclusion zones, 858-859
 - obligation to provide abortion services:
 - conscientious objection, 859-861
- Victoria
 - criminalisation to medicalisation, 853-854

Abortifacients – see Medical abortion

Access to health care

- special access to experimental treatments – *see*
Special access regimes

Accidents

- staged – *see* **Homicide**

**Advertising – see Sports-embedded gambling
advertising**

AFL

- supplements – *see* **Sport**

Africa

- ebola – *see* **Ebola**

Al-Hijama

- regulation (UK), 35-40
 - clinical effects & benefits, 36
 - practice in United Kingdom, 36-37
 - recommendations for statutes, training &
registration, 37-40

Alcohol – see also Energy drinks

- consumption & impairment of surgeons, 556-564
- determinants of blood alcohol levels, 561-562
- disciplinary actions for professional misconduct
 - by doctors exceeding safe consumption
of alcohol, 562-563
- impaired performance with alcohol
 - consumption, 559-561
- psychomotor requirements of surgeons, 558-559
- teenagers' access to (Australia), 419-432
 - controlled legalisation, 431-432
 - current regulation, 423-425

- ethics of intervention, 421-423
- secondary supply & the law, 425-428
- social policy dilemma, 419-421
- targeting sources of supply, 428-431

Amino acid sequences – see Open access

Anorexia nervosa

- patients' capacity to decide, 690-694

Australian Capital Territory

- abortion, 853-854

Automatism – see Zolpidem

Behaviour control – see Chemical restraint

Best interests

- capacity to decide, 379-381, 771-773

Biobanking – see also Open access

- disclosure of individual research results &
incidental findings, 89-95
- Australians' preferences & attitudes, 92-93
- background, 90
- international & national regulatory evidence,
93-94
- need for guidance, 91-92
- theoretical approaches, 90-91

Bioethics

- capacity to decide – *see* **Capacity to decide**
- genomic research, 322
- medical travel (book review), 970-972
- solitary confinement, 26
- special access regimes, 138-143
- teenagers' access to alcohol, 421-423

Blood donation

- Australian policy as it affects gay men, 915-934
- law, 920-927
 - domestic jurisprudence, 920-924
 - foreign law, 924-926
 - international law, 926-927
- science, 916-320
 - demographics, 920
 - false negatives, 918
 - history of HIV/AIDS, 916-917
 - modes of transmission & associated risk, 918-919
 - testing for HIV & window period, 917-918
- theory, 927-933
 - recognition & exclusion, 930-933
 - surveillance & control, 927-930

Caffeine – *see* **Energy drinks**

Canada

embryos – *see* **Embryos**
 solitary confinement, 29-30
 special access programmes – *see* **Special access regimes**

Cancer – *see also* **Breast cancer; Cervical cancer; Gynaecological cytopathology**

funding of high-cost medicines, 640-655
 discussion, 653-655
 implications for health resources allocation in Australia, 654
 value of the right to health, 653-654
 materials & methods of study, 642
 results of study, 642-653
 Australian human rights laws, 646
 domestic “right to medicines” policies, 648-653
 international “right to health” laws, 642-644
 international “right to high-cost medicines” laws, 645
 international “right to medicines” laws, 644-645
 other Australian laws that allude to a “right to health”, 647-648
 State & Territory human rights laws, 646-647

Capacity to decide

criteria, 678-694
 patients with anorexia nervosa, 690-694
 proposed model, 683-687
 relevance of proposed model, 687-690
 variability beyond understanding & choice, 679-682
 decision-making impairments
 consumer transactions, 756-762
 access to basic & essential services, 757-758
 equitable support models, 759-761
 ethical measures, 767-773
 mental capacity, competence & appropriate care, 768-769
 rights & best interests, 771-773
 roles, responsibilities & relationships, 770-771
 workable & practical balance, 769-770
 legally valid consent and, 371-386
 common law, 374-382
 consent & trespass, 377-378
 duty of care & negligence, 378-379
 impaired decision-making & best interest, 379-381
 legally valid consent, 376-377
 necessity, 381
 ethical principles relating to assessment of capacity, 372-374

autonomy, 372-373
 beneficence, 373
 justice, 374
 non-maleficence, 373-374
 legislation, 382-385
 mental health and, 905

Car accidents

staged – *see* **Homicide**

Chemical restraint

regulation in health care settings (UK), 15-19
 current regulation, 17-18
 human rights concerns, 16-17

Children (minors) – *see also* **Parental refusal of treatment for children**

access to alcohol – *see* **Alcohol**
 intersex – *see* **Intersex**
 solitary confinement, 22-23

Civil conscription

community pharmacy – *see* **Community pharmacy**

Clinical practice guidelines

legitimacy, 821-836
 court cases, 824-834
 bias & conflicts of interest, 832-834
 consensus, 825-827
 consultation, 827-828
 evidence, 829-832
 expertise, 824-825
 law, 834
 courts, 824
 meta-guidelines, 822-823

Clinical testing

regulation of trials (Australia), 337-341
 approving initiation of trials, 338-339
 dangers, 337-338
 monitoring ongoing trials, 339-340

Clinical trials – *see* **Clinical testing**

Cloud computing – *see* **Genomics**

Coercive community treatment – *see* **Mental health**

Communicable diseases

global control, 7-14
 funding, 12-13
 gender & global health governance, 13

Community pharmacy

corporatisation, 41-60
 Constitutional prohibition against civil

- conscription, 49-53
 - guarantee against managed care, 57-58
 - meaning of civil conscription, 53-54
 - obligation to prevent civil conscription, 58-59
 - practical compulsion, 56-57
 - “providers of medical services”, 51-53
 - current regulatory framework, 42-44
 - federal location rules, 42-43
 - Harper Competition Policy Review, 44
 - opposition to: loss of quality medical services, 46-49
 - lessons from other jurisdictions, 46-48
 - potential impact in Australia, 48-49
 - State & Territory ownership laws, 43-44
- Community treatment orders** – *see* **Mental health**
- Compassionate use** – *see* **Special access regimes**
- Complementary medicine** – *see also* **Al-Hijama**
 - practitioners
 - disciplined for misconduct (Australia, 2010-2016), 788-802
 - analysis of commonest types of misconduct, 796-802
 - inappropriate medical care, 799-802
 - sexual misconduct, 796-799
 - cases, 790-791
 - complaints, 789-790
 - types of misconduct, 791-796
 - gender of practitioners, 793
 - outcomes & protective orders, 793-795
 - removal from practice, 795-796
- Conscientious objection**
 - obligation to provide abortion services (NSW), 859-861
- Consent**
 - genetic tests – *see* **Genetic tests**
 - genomics, 323-324
 - informed – *see* **Informed consent**
 - legally valid – *see* **Capacity to decide**
 - special access regimes, 138-143
- Consumers**
 - decision-making impairments – *see* **Capacity to decide**
- Coroners**
 - inquests – *see* **Paramedics**
- Damages**
 - Al Muderis v Duncan (No 3), 749-753
- Deceased persons**
 - genetic tests – *see* **Genetic tests**
- Decision-making capacity** – *see* **Capacity to decide**
- Defamation**
 - Al Muderis v Duncan (No 3), 750-753
- Dental assistants**
 - profession (South Africa), 707-721
 - conception of health professions, 708-712
 - critical analysis of dental assistants as health profession, 717-720
 - professionalisation of dental assistants, 712-717
- Designer drugs** – *see* **New psychoactive substances**
- Development, right to** – *see* **Ebola**
- Diagnosis**
 - delay in – *see* **Neurodegenerative diseases**
- Disability** – *see* **Mental health**
- Disciplinary hearings**
 - decisions (New Zealand, 2004-2014), 239-251
 - aim of study, 244
 - complaint pathway to Health Practitioners Disciplinary Tribunal (HPDT), 242-244
 - data, 244
 - discussion, 249-250
 - limitations of study, 250
 - Health Practitioners Disciplinary Tribunal, 241-242
 - medico-legal framework, 239-241
 - method of study, 244-245
 - results of study, 245-249
 - disciplinary characteristics, 249
 - procedural & hearing characteristics of medical practitioners & nurses, 249
 - practitioner & procedural characteristics, 245-248
 - Health Practitioners Disciplinary Tribunal (New Zealand) cases (2003-2014)
 - aim of study, 592-593
 - discussion, 594-596
 - method of study, 593
 - practitioners’ health conditions, 593-594
 - name suppression (New Zealand), 504-515
 - conclusion, 515
 - discussion, 514-515
 - limitations of study, 514-515
 - guilty findings & guilt not established, 510-511
 - Health & Disability Commissioner, 515
 - health disciplinary settings, 506-507

- Health Practitioners Competence Assurance Act, 507
- Health Practitioners Disciplinary Tribunal (HPDT), 506-507
- interim name suppression, 508
- open justice, 505
- outcome of other litigation, 511
- permanent name suppression, 509-510
 - character factors, 510
 - impact on other third parties, 510
 - interests of others, 510
 - practitioner interests, 509-510
 - public interest, 509
- quantitative study, 511-512
 - method, 511-512
 - results, 512-514
- professional misconduct by doctors exceeding safe consumption of alcohol, 562-563

- DNA – see Open access**

- Doctor-patient relationship – see also Medical practitioners; Sexual misconduct**
- duty to advise of risks to patients, 525-536
 - Australian decision of Rogers v Whitaker, 530-531
 - Montgomery decision, 531-536
 - Bolam decision, 526-527
 - controversies after Bolam, 527-530
 - Montgomery decision, 531-536
 - ramifications of Montgomery decision, 536-538
- litigation (doctors suing patients)
 - Al Muderis v Duncan (No 3), 749-753
 - award of damages, 753
 - defamatory conduct, 750-753
 - significance of judgment, 754-755

- Doping – see Sport**

- Drug monitoring – see Substance use**

- Drug testing**
 - workplace, 398-418
 - conclusion, 417-418
 - drug-related risks to patient safety, 408-412
 - history, 399-403
 - Australian medical practitioners, 401-403
 - United Kingdom, 401
 - United States, 399-400
 - more proactive need, 403-408
 - privacy issues, 413-417

- Drug use – see Substance use**

- Drugs, illicit – see New psychoactive substances**

- Drugs, performance-enhancing – see Sport**

- Drugs, therapeutic – see also Zolpidem**
- behaviour control – see **Chemical restraint**
- cancer – see **Cancer**
- non-medical prescribing
 - asynchronous legislation, 656-661
 - profession-specific prescribing, 657-658
 - eligible midwives, 657
 - optometrists, 658
 - podiatrists, 657
- discussion, 660-661
- methods of study, 658
- results of study, 658-660
 - eligible midwives, 658-659
 - optometrists, 660
 - podiatrists, 659

- Duty of care**
 - capacity to decide, 378-379
 - vaccination – see **Vaccination**

- Ebola**
 - epidemic in West Africa (2014), 722-740
 - African experience of right to development, 727-730
 - Ebola virus & development, 730-740
 - access to medicines & intellectual property, 735-740
 - right to development, 724-727
 - global response to outbreak, 7-14

- Electronic commerce**
 - genomics, 324-327

- Electronic health records (EHR)**
 - “My Health Record system” (Australia)
 - whose benefit, 283-296
 - background, 287-288
 - letter to the Editor, 576-578
 - objects & benefits, 292-296
 - operation of system, 288-290
 - patients’ control, 290-291

- Embryos – see also Stem cell therapies**
- storage
 - IVF patients
 - fertility insurance benefit, 886-899
 - Canadian legal context of embryo disposition, 88
 - lessons for law & policy, 897-899
 - materials & methods of study, 889-890
 - temporal & spatial liminality of embryo cryopreservation, 890-897

End-of-life decisions – see also Withdrawal of life support

- legal proxies (Italy), 959-969
 - Bill 2350: nomination of surrogate, 964-966
 - importance of legal proxies, 962-964
 - nomination of support guardian for health care decisions, 966-968
- New Zealand
 - law reform (book review), 516-517

Energy drinks – see also Alcohol

- regulation (Australia), 433-454
 - conclusion, 453-454
 - definition of “formulated caffeine beverage”, 434-443
 - health implications, 437-443
 - marketing, 443-452
 - alcohol regulation, 444-446
 - Australian law for energy drinks, 446-448
 - caffeine regulation, 444
 - law in other countries, 448-452
 - recommendations, 452-453

England and Wales – see United Kingdom**Epidemics – see also Avian influenza virus; Ebola; Pandemic infections****Ethics – see Bioethics****European Court of Human Rights**

- solitary confinement, 28-29

Expanded access scheme – see Special access regimes**Experimental treatments – see Special access regimes****Expert evidence**

- Australia, 628-639
 - Attwells decision, 30-632
 - conclusion, 638-639
 - immunity afforded to expert witnesses, 632-638

Forensic procedures

- feature-comparison methods in criminal courts (US), 297-302
- PCAST report on scientific validity, 299-301
- responses to report, 301

Gambling

- sport – see **Sport-embedded gambling advertising**

Gay advance defence – see Homosexual advance defence**Gay men**

- blood donation – see **Blood donation**

Genetic tests

- non-consensual
 - regulation (Australia), 150-165
 - argument for new offence, 153-154
 - consent and deceased individuals, 157-158
 - expansion of offence to include samples from deceased persons, 154-156
 - potential issues with restriction of genetic testing of samples from deceased individuals, 162-165
 - benefits of research, 162
 - clarity of family relationships, 164
 - clinical benefits, 163-164
 - identification of remains, 164-165
 - protection of genetic privacy, 151-153
 - risks arising from genetic testing of samples from deceased individuals, 158-161
 - harm to individuals, 158-159
 - harm to relatives, 160
 - harm to the community, 160-161
 - samples from deceased individuals, 156-157

Genetics – see Open access; Patenting genetic material; Pharmacogenomics**Genitalia, indeterminate – see Intersex****Genomics – see also Biobanking; Open access; Pharmacogenomics**

- cloud computing (Australia), 314-336
 - case studies, 330-333
 - 23andMe, 331-333
 - National Computational Infrastructure (NCI), 330-331
 - security, 332-333
- conclusions & recommendations, 333-336
 - co-operation, 333-334
 - regional models of consent, 334-335
 - sanitary & phytosanitary model, 336
 - trans-Pacific right to be forgotten, 335-336
- potential effect, 324-330
 - electronic commerce, 324-327
 - investor–state dispute settlement, 327-330
- regulation, 318-324
 - cross-border confidentiality, 323
 - disclosure without consent, 323-324
 - ethical research, 322
 - international standards, 322-323
- research use, 315-318

Global health governance – *see* **Communicable diseases**

Guardians
support – *see* **End-of-life decisions**

Harper Competition Policy Review
community pharmacy, 44

Health and Disability Commissioner (New Zealand)
disciplinary hearings, 515

Health law
New Zealand (book review), 267-268

Health Practitioner Disciplinary Tribunal (New Zealand)
disciplinary hearings – *see* **Disciplinary hearings**
nurses – *see* **Nurses**

Health practitioners – *see also* **Complementary medicine; Dental assistants; Medical practitioners; Midwives; Nurses; Optometrists; Paramedics; Pharmacists; Podiatrists**
disciplinary cases – *see* **Disciplinary hearings**
health conditions (New Zealand), 593-594
national regulation & accreditation
mandatory notification
vexatious, misconceived & avoidable reports, 579-589
discussion, 586-588
findings of study, 582-586
qualitative study method, 581-582
strengths & limitations of study, 588
non-medical prescribing – *see* **Drugs, therapeutic**
regulation of substance-addicted doctors (Vic, 1933-1948), 597-615
lessons from the past, 612-615
Medical Act 1933 & Victorian legislature's attitude, 599-601
Medical Board of Victoria's regulation, 602-606
evaluation of, 606-612
medical thinking about substance addiction, 601-602
statements on solitary confinement, 32-33

Health systems – *see* **National health systems**

HIV/AIDS
history of, 916-917
modes of transmission & associated risk, 918-919
pharmacogenomics in treatment – *see* **Pharmacogenomics**
testing for & window period, 917-918

Homicide
staged as car accident (US), 493-503
conclusion, 503
discussion, 500-502
future directions, 502
limitations of study, 502
literature, 494-495
method of study, 495-496
procedure, 496
sample, 495-496
results, 496-500
crime/victim/offender elements, 496-499
elements of staging, 499-500

Homosexual advance defence
stigma and, 935-958
criminal law & stigma of homosexuality, 949-957
cultural context, 949-951
language, 953-957
offenders & victims, 951-953
High Court response, 942-946
history & definition of stigma, 946-948
history of homosexual panic defence & homosexual advance defence, 942
homosexual advance & provocation, 939-942
law & homosexuality, 936-939

Homosexual men
blood donation – *see* **Blood donation**

Human body
state & bodily autonomy (book review), 741-742

Human rights
cancer – *see* **Cancer**
chemical restraint, 16-17

Humanitarian access – *see* **Special access regimes**

Huntington's disease
right to sue for delay in diagnosis, 275-282

Hypnotic drugs – *see* **Zolpidem**

In-vitro fertilisation – *see* **Embryos**

Incidental findings – *see* **Biobanking**

Individual research results – *see* **Biobanking**

Informed consent
prenatal testing, 214-216

International Health Regulations (WHO)
global responses to outbreaks of communicable diseases, 8-11

Intersex (Disorders of sex development, DSD)
 “treatment” of children as a Special Medical Procedure, 870-885
 Australian law & “sex reassignment”, 881-884
 intersex children, surgery & consequences, 871-875
 intervention as Special Medical Procedure, 875-881

Investor–state dispute settlement
 genomics, 327-330

In-vitro fertilisation – *see* **Embryos**

Islamic perspectives
 al-Hijama – *see* **Al-Hijama**

Italy
 end-of-life decisions – *see* **End-of-life decisions**

IVF – *see* **Embryos**

Judicial review – *see* **Workers’ compensation**

Juveniles – *see* **Children (minors)**

Legal highs – *see* **New psychoactive substances**

Litigation
 medical – *see* **Medical litigation**

Medical abortion
 regulation (Australia), 221-238
 background, 222
 legal risks of early medical abortion, 232-237
 reform jurisdictions, 232-233
 restrictive jurisdictions, 233-237
 measurable clinical risks, 225-228
 mifepristone, 222-225
 off-site abortion, 229-232

Medical error
 no-fault system (New Zealand)
 professional accountability, 303-313
 workings of system, 304-307

Medical litigation – *see also* **Medical negligence**
 delay in diagnosis – *see* **Neurodegenerative diseases**

Medical negligence – *see also* **Damages; Duty of care**
 capacity to decide, 378-379
 delay in diagnosis – *see* **Neurodegenerative diseases**

Medical practitioners – *see also* **Complementary medicine; Doctor-patient relationship; Duty of care**
 alcohol impairment of surgeons – *see* **Alcohol**
 disciplinary hearings – *see* **Disciplinary hearings**
 drug testing – *see* **Drug testing**
 duty to rescue, 695-706
 cases involving medical practitioners, 697-702
 common law in Australia, 696-697
 comparison of approaches, 705-705
 statutory duty & protection of rescuers, 702-705
 registration
 regulation of substance-addicted doctors (Vic, 1933-1948), 597-615
 lessons from the past, 612-615
 Medical Act 1933 & Victorian legislature’s attitude, 599-601
 Medical Board of Victoria’s regulation, 602-606
 evaluation of, 606-612
 medical thinking about substance addiction, 601-602
 withdrawal of life support – **Withdrawal of life support**

Medical tourism – *see* **Medical travel**

Medical travel
 law & ethics (book review), 970-972
 stem cells (book review), 972-975

Medicines – *see* **Drugs, therapeutic**

Mental capacity – *see* **Capacity to decide**

Mental health
 coercive community treatment, 900-914
 capacity, 905
 Convention on the Rights of Persons with Disabilities (CRPD), 905-907
 criteria for community treatment orders (CTOs), 903-904
 effect of CTOs, 904-905
 exposing the flaws, 907-914
 history of CTOs, 902-903
 restraints – *see* **Restraints and seclusion**
 solitary confinement – *see* **Solitary confinement**

Midwives
 prescribing – *see* **Drugs, therapeutic**

Mifepristone
 access to (NSW), 862

Minors – *see* **Children (minors)**

“My Health Record” system – *see* **Electronic health records**

National health systems

- responses to global emergencies, 10
- regional responses, 11-12

Necessity

- capacity to decide, 381

Negligence

- civil liability – *see* **Vaccination**

Negligence, medical – *see* **Medical negligence**

Neurodegenerative disease

- right to sue for non-communication or delay in diagnosis, 275-281
 - ABC decision, 276-281
 - ramifications for Huntington's disease, 281-282
 - Smith decision, 279-281

New psychoactive substances, 763-766

- Australia, 764-765
- chemistry, 764
- implications, 766
- laboratory analysis, 765-766
- ongoing monitoring, 766

New South Wales

- abortion – *see* **Abortion**
- access to mifepristone, 862

New Zealand – *see also* **Health and Disability Commissioner (New Zealand); Health Practitioner Disciplinary Tribunal (New Zealand)**

- disciplinary hearings – *see* **Disciplinary hearings**
- end-of-life decisions (book review), 267-268
- health law (book review), 267-268
- Health Practitioner Competence Assurance Act
 - health disciplinary setting, 506
- medical error
 - no-fault system – *see* **Medical error**
- nurses – *see* **Nurses**
- prenatal screening, 204-205
- statutory privilege – *see* **Statutory privilege**

“No fault” systems – *see* **Medical error**

Non-invasive prenatal testing – *see* **Prenatal testing**

Non-consensual genetic testing – *see* **Genetic testing**

Nurses – *see also* **Midwives**

- disciplinary hearings – *see* **Disciplinary hearings**
- residential care workforce
 - professional discipline (New Zealand), 803-820
 - discussion, 815-820

ageism, 818-819

Health Practitioner Disciplinary Tribunal
decisions in residential care settings,
815-816

limitations of study, 820

systemic workforce issues, 816-818

therapeutic approach, 819-820

elder neglect & abuse, & complaints system,
806-810

Health Practitioner Disciplinary Tribunal
study, 801-815

learning from complaints & disciplinary
action, 805-806

residential care services, 803-805

Open access

- DNA, RNA & amino-acid sequences, 96-118
 - data & information obligations under
international agreements, 112-115
- databases, 99-105
- discussion, 115-118
- Human Genome Project, 105-108
- recent developments, 108-112

Optometrists

- prescribing – *see* **Drugs, therapeutic**

Pandemics – *see* **Ebola**

Paramedics

- regulation
 - coronial inquests, 616-627
 - coronial consideration of paramedicine, 619-
626
 - regulation & regulatory issues, 617-619
 - role of paramedics, 617

Parental refusal of treatment for children

- Kiszko litigation, 61-71
 - 1st decision, 63-64
 - 2nd decision, 64-65
 - 3rd decision, 65-68
 - background, 62-63
 - lessons, 68-71

Patenting genetic material

- access to gene-based research materials & data,
72-88
 - accessing data associated with gene patents, 79-
81
- biomedical research & genetic diagnostic
testing, 73-77
 - genetic variation data, 75-77
 - patents & material transfer agreements, 73-75
- conclusion, 87-87

-
- mechanisms for accessing patented research materials, 77-79
 - options for accessing materials & data, 81-87
 - legal mechanisms, 84-87
 - genetic variation data, 85-878
 - march-in rights, 84-85
 - private contracting, 82-84
 - public policy & regulation, 81-82
 - privacy, 81-82
 - human genes
 - legal issues, 181-202
 - concluding comment, 201-202
 - history of patent law, 182
 - legislative history & political debate, 200-201
 - “manner of manufacture”, 183-198
 - claimed & naturally occurring products, 196-197
 - Myriad Genetics case in Federal Court, 187-190
 - Myriad Genetics case in High Court, 191
 - product or process, 193-196
 - policy, moral & social reasons, 197-198
 - science of genes & DNA, 185-186
 - test in NRDC case, 191-193
 - novelty, inventive step, useful application, & not secretly used before, 198-200
 - requirements granting patent, 182-183
 - Pharmacists**
 - community ownership – *see* **Community pharmacy**
 - Pharmacogenomics**
 - treatment of HIV/AIDS, 166-180
 - abacavir & hypersensitivity, 178-179
 - activism & HIV/AIDS, 171-173
 - discovering HIV, 169-171
 - regulatory reform improving access to medicines, 173-176
 - translation into clinical practice, 178-179
 - translation of new knowledge, 168-169
 - Pharmacy ownership**
 - community ownership – *see* **Community pharmacy**
 - Podiatrists**
 - prescribing – *see* **Drugs, therapeutic**
 - Post-traumatic stress disorder (PTSD) – *see also***
 - Psychiatric injury**
 - judicial recognition in crime victims (Australia), 478-492
 - analysis of victim PTSD in Australian criminal judgments, 487-492
 - cases where mentioned in passing, 491-492
 - cases where somewhat relevant, 490-491
 - cases where “very relevant”, 488-490
 - Australian criminal judgments, 481-487
 - limitations of research, 483
 - methodology of review, 482-483
 - results, 484-487
 - conclusion, 492
 - Prenatal diagnosis – *see* Prenatal testing**
 - Prenatal screening – *see* Prenatal testing**
 - Prenatal testing**
 - non-invasive, 203-220
 - expansion to panels, 210-212
 - additional trisomies, 201
 - microdeletion & microduplication syndromes, 211-212
 - sex chromosome abnormalities, 201-211
 - implications for policy, 213-219
 - informed consent, 214-216
 - interface with abortion law, 218-219
 - regulatory oversight & quality assurance (US), 216-218
 - standardisation, 216
 - prenatal screening (New Zealand), 204-205
 - science, 206
 - technical limitations, 206-209
 - false positives & negatives, 207-209
 - foetal fraction, 206-207
 - Privacy**
 - genetic, 81-82 – *see also* **Genetic tests**
 - Privilege – *see* Statutory privilege**
 - Property**
 - sperm – *see* **Sperm**
 - Provocation – *see* Homosexual advance defence**
 - Proxy decision-making – *see* End-of-life decisions**
 - Quality assurance activities**
 - statutory privilege – *see* **Statutory privilege**
 - Reproductive rights – *see* Abortion**
 - Rescue**
 - duty of doctor to – *see* **Medical practitioners**
 - Residential care**
 - workforce – *see* **Nurses**
 - Restraints and seclusion**
 - chemical – *see* **Chemical restraint**
 - solitary confinement – *see* **Solitary confinement**

- Right to be forgotten**
genomics, 335-336
- Right to development** – *see* **Ebola**
- Right to health**
cancer – *see* **Cancer**
- Right to medicines**
cancer – *see* **Cancer**
- Right to sue**
non-communication or delay in diagnosis – *see* **Neurodegenerative disease**
- Rights**
capacity to decide, 771-773
- Semen donors** – *see* **Sperm**
- Sewage**
wastewater analysis – *see* **Substance use**
- Sex reassignment** – *see* **Intersex**
- Sexual misconduct**
complementary medicine practitioners, 796-799
- Sleep-related behaviour** – *see* **Zolpidem**
- Solitary confinement**
as correctional intervention, 20-34
correctional perspectives, 33
definitions, 21-22
ethical perspectives, 26
health professional advocacy, 32-33
juvenile offenders, 22-23
legal perspectives, 26-32
 Australia, 30-32
 Canada, 29-30
 European Court of Human Rights, 28-29
 international instruments, 32-38
 United States, 29
mental disorder, 23-25
 empirical studies, 24-26
 reactions, 23-24
need for reform, 33-34
- South Africa**
dental assistants – *see* **Dental assistants**
- Special access regimes**, 122-148
Australia, 126-128
 authorised prescriber scheme, 127-128
 special access scheme, 126-127
authorisation for special access use, 136-143
ethics & consent requirements, 138-143
 whose authority? 136-138
- Canada**
medical devices special access programme, 126
special access programme, 125-126
comparative analysis, 122-123
data collection & reporting requirements, 143-147
eligibility & criteria, 128-136
 medical justification, 128-132
 relationship with clinical trials & product development, 132-136
- United States**, 123-125
access to unapproved devices, 124-125
expanded access for unapproved drugs, 123-124
- Special Medical Procedures** – *see* **Intersex**
- Sperm**
proprietary interest in cryopreserved sperm
Roblin case, 864-869
 facts & claims, 865
 future of law, 867-868
 legal issues, 865-866
- Sport**
performance-enhancing drugs
Essendon Football Club supplements saga, 565-575
anti-doping regulatory framework, 566-567
Court of Arbitration of Sport verdict, 569-570
history of the saga, 568-569
regulators & performance-enhancing substances, 571-574
Swiss Federal Tribunal appeal, 571
- Sports-embedded gambling advertising**
public health legislation prohibiting, 774-787
Australian sports betting market, 782-783
Betfair decision (High Court), 778-779
existing Australian legislation, 776-778
industry self-regulation & codes, 779-780
lessons from other jurisdictions, 783-785
public health problems, 780-782
recent bills, 774-776
tobacco legislation as model, 785-787
- Staged accidents** – *see* **Homicide**
- Standards** – *see* **Clinical practice guidelines**
- Statutory privilege**
Australia, 255-258
quality assurance activities (New Zealand), 252-266
 analysis of notices, 258-260
 background, 253
 discussion, 260-265

-
- Health Practitioner Competence Assurance Act
2003, 253-254
rationale, 254-255
- Stem cell therapies**
medical tourism (book review), 972-975
- Stigma** – *see* **Homosexual advance defence**
- Substance use**
doctors – *see* **Medical practitioners**
wastewater analysis, 837-849
chemistry, wastewater analysis & new
paradigms, 847-848
drug policy & information sources (Australia),
838-841
chemistry in monitoring, 841
monitoring systems, 839-841
other mechanisms, 841
pilot national study, 844-847
use of wastewater analysis, 841-844
how it works, 843-844
- Supplements** – *see* **Sport**
- Surgeons** – *see* **Medical practitioners**
- Surrogates**
end-of-life decisions – *see* **End-of-life decisions**
- Surveillance devices** – *see* **Telephones**
- Teenagers** – *see* **Children (minors)**
- Telephones**
smartphone monitoring of people with health
conditions, 387-397
discussion & conclusion, 396-397
listening or surveillance devices, 390-393
passive voice recording, 393-394
technological approaches, 394-396
automating analysis, 394-395
geolocation-based limiting of audio
recording, 395
non-human conversion partners, 396
voice identifiability, 395
voice and communication monitoring, 388-390
- Therapeutic privilege** – *see* **Statutory privilege**
- Tobacco**
legislation, 785-787
- Tort law** – *see* **Damages; Medical error; Medical
negligence; Trespass**
- Trespass**
capacity to decide, 377-378
- United Kingdom**
chemical restraint, 15-19
regulation of Al-Hijama – *see* **Al-Hijama**
- United Nations High-level Panel on the Global
Response to Health Crises**, 7-14
- United States**
forensic procedures – *see* **Forensic procedures**
prenatal testing, 216-218
solitary confinement, 29
special access regimes – *see* **Special access
regimes**
staged car accidents – *see* **Homicide**
- Vaccination**
civil liability of non-vaccinators, 662-677
liability in negligence, 66-676
breach of duty, 667-672
causation, 672-676
duty of care, 666-667
vaccination landscape, 663-666
- Vexatious notification** – *see* **Health practitioners**
- Victims of crime** – *see* **Post-traumatic stress
disorder**
- Victoria**
abortion, 853-854
medical practitioners – *see* **Medical practitioners**
workers' compensation – *see* **Workers'
compensation**
- Wastewater analysis** – *see* **Substance use**
- Wet-cupping** – *see* **Al-Hijama**
- Withdrawal of life support** – *see also* **End-of-life
decisions; Euthanasia; Sanctity of life
principle**
attitudes of doctors, 342-355
conclusion, 354-355
discussion, 353-354
measures, 344-346
methods of study, 343-344
results, 346-353
knowledge of law & practice of doctors, 356-370
conclusion, 369-370
discussion, 367-369
methods of survey, 358-359
results, 359-367

Withholding life-sustaining treatment – *see*
Withdrawal of life support

Workers' compensation

Victorian Medical Panels
judicial review of decisions, 538-555
 grounds for relief, 544-555
 history & procedure of judicial review, 542-544
 referral process, 539-540
 workload, 540-542

World Health Organization (WHO)

global public health emergencies, 10-17
International Health Regulations – *see*
International Health Regulations

Zolpidem (hypnotic)

complex sleep-related behaviour & volition, 455-477
 automatism, 469-474
 conclusion, 477
 criminal conduct, 467-469
 description of Zolpidem, 457-464
 adverse effects, 458-460
 complex behaviours performed in sleep-like state, 46-462
 incidence of adverse effects (Australia), 462-464
 evaluating clinical research, 464-466
 regulation of Zolpidem, 466-467
 unresolved issues, 474-476
 level of complexity of behaviour, 476
 nature of "sleep-like state", 474-476